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Abstract
Background: Severe anaemia can develop in the aftermath of Plasmodium falciparum malaria
because of protracted bone marrow suppression, possibly due to residual subpatent parasites.
Materials and methods: Blood was collected from patients with recent malaria and negative
malaria microscopy. Detection of the Plasmodium antigens, lactate dehydrogenase (Optimal®),
aldolase and histidine rich protein 2 (Now malaria®) were used to differentiate between patients
with (1) no malaria, (2) recent cleared malaria, (3) persistent P. falciparum infection. Red cell
distribution width (RDW), plasma levels of soluble transferrin receptor (sTfR) and erythropoietin
(EPO) were measured as markers of erythropoiesis. Interleukin (IL) 10 and tumour necrosis factor
(TNF)α were used as inflammation markers.
Results: EPO was correlated with haemoglobin, irrespective of malaria (R = -0.36, P < 0.001).
Persistent P. falciparum infection, but not recent malaria without residual parasites, was associated
with bone marrow suppression i.e., low RDW (P < 0.001 vs. P = 0.56) and sTfR (P = 0.02 vs. P =
0.36). TNF-α and IL-10 levels were not associated with bone marrow suppression.
Conclusion:  In the treatment of malaria, complete eradication of parasites may prevent
subsequent development of anaemia. Severely anaemic children may benefit from antimalarial
treatment if antigen tests are positive, even when no parasites can be demonstrated by microscopy.
Introduction
Anaemia is a common, life-threatening complication of
Plasmodium falciparum malaria in African infants and
young children. The anaemia develops when accelerated
removal of erythrocytes is not compensated by the bone
marrow. Bone marrow suppression is generally present in
all malaria patients [1] and has also been described in
asymptomatic  P. falciparum infection [2]. The fact that
some malaria patients develop severe anaemia, whereas
others retain normal or near normal haemoglobin (Hb)
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must thus be explained by the amount of erythrocyte
destruction during the period until return of normal bone
marrow function. The anaemia may either develop rap-
idly with severe, acute haemolysis, or take a slow smoul-
dering course, with a relatively slow rate of erythrocyte
destruction in the presence of persistent bone marrow
suppression [3]. Data on the duration of bone marrow
suppression after a malaria attack are conflicting. In some
studies there has been evidence of hypoproliferative eryth-
ropoiesis and dyserythropoiesis for weeks following treat-
ment [4,5], while other studies have shown that bone
marrow suppression is reversed rapidly after treatment
[1,6].
In areas where malaria is endemic, a high number of chil-
dren with severe anaemia but without detectable parasites
are hospitalized each year coinciding with the peak of
malaria transmission. The history of recent febrile illness
and the presence of detectable circulating antigens
strongly suggest that these children suffer from the late
effects of a recent malaria attack [7]. The question is
whether there are signs of bone marrow suppression in
these patients, and if so, whether this bone marrow sup-
pression is due to a sustained effect of the malaria attack
or to the persistence of parasites that are undetectable by
routine microscopy. In the latter case, it is possible that
these patients would benefit from a repeated course of
antimalarial treatment.
Patients with severe malarial anaemia have an increased
ratio between the pro-inflammatory cytokine, tumour
necrosis factor (TNF)-α, and the anti-inflammatory
cytokine, interleukin (IL)-10 [8], and it has been proposed
that inflammatory cytokines may be a causative factor for
malarial anaemia [9,10]. If so, protracted bone marrow
suppression in the aftermath of a malaria attack might be
due to persistence of a dysregulated inflammatory
response. However, mild and moderate malarial anaemia
is not associated with an inverse ratio between TNF-α and
IL-10 [2].
The purpose of the present study was to test the hypothe-
sis that an impaired erythropoietic response to anaemia is
associated with a persistent malarial infection in patients
without microscopically detectable parasites. In order to
differentiate between recent and persistent P. falciparum
infection, two rapid tests for soluble malarial antigens,
Now®  ICT Malaria P.f/P.v (Binax, US) and Optimal®
(DiaMed AG, Schweiz) were performed. Binax is based on
detection of histidine rich protein 2 (HRP2) and aldolase
and can remain positive for weeks following treatment of
the infection [11]. Optimal®, on the other hand, detects
parasite derived lactate dehydrogenase (pLDH) and test
results are positive only in the presence of live parasites
[12].
Red cell distribution width (RDW) and plasma levels of
erythropoietin (EPO) and soluble transferrin receptor
(sTfR) were measured as markers of erythropoiesis. RDW
is a measure of size variation in red blood cells and is
increased when erythropoiesis is stimulated [13]. sTfR is
secreted mainly by erythroblasts, and plasma levels are
increased when turnover in the bone marrow is raised as
in haemolytic anaemia, whereas levels are normal in the
anaemia of chronic disease [14]. Plasma levels of TNF-α
and IL-10 were analysed to determine if the bone marrow
suppression was correlated to dysregulated inflammation.
Materials and methods
The study took place at the Department of Child Health,
Korle Bu Teaching Hospital, Accra, Ghana during the
malaria season, July and August, 2003. Two groups of
children aged 0.5–12 years were consecutively recruited.
Both groups consisted of children with a presumptive or
confirmed diagnosis of recent malaria but without detect-
able parasites in Giemsa-stained blood films, examined
by ordinary microscopy.
Group 1
Patients admitted to the emergency room with a presump-
tive diagnosis of acute malaria but with a negative micro-
scopic test for malaria. The majority of these patients had
received treatment for malaria either at home or in various
health facilities prior to being referred to hospital. Those
who had haemoglobin (Hb) ≤ 5 g/dl or Hb ≥ 8 g/dl were
included, unless they had a history of a recent trauma or
bleeding. Four hundred and five patients with the same
age and sex distribution and with proven malaria by
microscopy acted as a positive control group.
Group 2
Children who came for follow-up on day three after initi-
ation of treatment for acute, uncomplicated falciparum
malaria at the health clinic attached to the hospital and
who had cleared their parasitaemia microscopically.
Patients with febrile illness other than malaria, with
severe malaria, concomitant infections or known chronic
disease were excluded. The children had received amodi-
aquine, artesunate or a combination of the two as part of
an ongoing drug trial.
Children were enrolled after informed consent from par-
ents or guardians. The ethics and protocol review commit-
tee at the University of Ghana Medical School had
approved the study.
Blood was collected in EDTA-coated tubes and examined
using an automated haematology analyser (Sysmex, KX-
21, Germany). Giemsa-stained blood films were prepared
on day 0 (group 1) and on day 0 (i.e. prior to inclusion), 3
and 7 (group 2). Blood films were considered to be nega-Malaria Journal 2005, 4:56 http://www.malariajournal.com/content/4/1/56
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tive if 200 leucocytes had been counted without finding
parasites, corresponding to a detection level of approxi-
mately 50 parasites/µL. Antigen detection was performed
on whole blood from day 0 (group 1) and day 3 (group 2).
The rapid diagnostic tests, Now®  ICT Malaria P.f/P.v
(Binax, US) and Optimal® (DiaMed AG, Schweiz), were
used according to the manufacturer's instruction.
The EDTA-plasma was subsequently collected by centrifu-
gation and stored at -20°C until analysis. Plasma concen-
trations of EPO, sTfR, TNF-α and IL-10 were measured
using commercial ELISA kits according to the manufac-
turer's instructions (EPO, sTfR and IL-10, R&D Systems,
MN, USA and TNF-α, BioSource International, CA, USA).
Statistics
All data, except haemoglobin, were logarithmically trans-
formed to achieve normal distribution. Differences
between groups were analysed using two-tailed student's
t-test, except differences in haemoglobin levels that were
analysed by Mann Whitney two sample rank sum test.
Associations between parameters were analysed by multi-
ple regression analyses. P-values < 0.05 were considered
statistically significant. All calculations were performed
using Stata SE 8.0 (Stata Corporation, TX, USA)
Results
Forty eight patients were enrolled into group 1: 24 with
severe anaemia and 24 with Hb ≥ 8 g/dl. Two (8.3 %) of
the patients with severe anaemia and 15 (62.5 %) of those
with Hb ≥ 8 g/dl had no detectable malaria antigens and
were, thus, unlikely to suffer from malaria ('No malaria',
Table 1). Of the remaining 31 patients, all had a positive
HRP-2 test. Sixteen also had a positive pLDH test, sugges-
tive of persistent malaria, whereas 15 had a positive HRP-
2 test only, suggestive of recent malaria. Among the
patients with a positive antigen test, 25 reported to have
taken some antimalarial medication prior to admission,
four had not received treatment and information was
missing for two patients. Forty seven patients were
enroled into group 2. Their median parasite density on day
0 was 25,633 parasites/µL (25th – 75th percentiles: 5096
– 70,755). On the day of inclusion (day 3) all had unde-
tectable parasitaemia by microscopy but had a positive
HRP-2 test. Only eight had signs of persistent parasitae-
mia as indicated by the pLDH test. In both groups,
patients with persistent malaria tended to have lower Hb
than those with recent malaria; although in group 1, the
difference did not reach statistical significance (group1: P
= 0.19 and group 2: P = 0.04, Table 1). In order to simplify
the result presentation, the two groups are combined,
based on the assumption that subpatent P. falciparum
infection played a similar role in both groups. However,
since the groups had different age distribution and the
clinical similarity between the groups could not be estab-
lished, the data were also analysed separately for the
groups. As indicated in the text, this did not affect the con-
clusions of the study.
Erythropoiesis
The bone marrow response to low Hb was compared
between patients with positive pLDH, (persistent malaria,
n = 24) and those with negative pLDH, (recent malaria or
no malaria, n = 71) in order to detect an effect of persist-
ent P. falciparum infection on erythropoiesis. Both RDW
and sTfR increased in response to low Hb as indicated by
a negative correlation between RDW and Hb and between
sTfR and Hb. However, the levels of RDW and sTfR were
lower in patients with persistent infection (filled symbols)
than in those with recent malaria or without signs of
malaria (open symbols, Figure 1A and 1B). In a multivar-
iate regression analysis with haemoglobin and test results
for pLDH and HRP2 as explanatory variables, a positive
test for pLDH, but not a positive test for HRP2 alone, was
significantly associated with reduced levels of RDW and
sTfR (Table 2). For this analysis, all patients in group 1
Table 1: Patient characteristics
Group 1 Group 2
Persistent malaria Recent malaria No malaria Persistent malaria Recent malaria
Number of patients 16 15 17 8 39
Age1 (years) 2 (1–12) 4 (0.5–10) 2 (0.5–12) 5.8 (1.5–10) 5.8 (1–12)
Temperature on admission1 (°C) 37.0 (36.0–38.5) 38.0 (36.7–38.6) 37.5 (36.6–39.5) 37.2 (36.8–38.8) 38.2 (36.0–40.0)
Sex (boys:girls) 12:4 7:8 10:7 5:3 23:15
Haemoglobin1 (g/dl) 3.4 (2.1–10.2) 4.4 (1.6–11.6) 9.8 (1.5–11.8) 6.6 (4.7–10.5) 9.2 (5.2–12.0)
TNF-α (pg/ml)2 16.2 (6.9–38.0) 13.5 (6.5–27.5) 5.4 (1.2–23.4) 6.2 (0.6–63.1) 8.7 (5.5–13.5)
IL-10 (pg/ml)2 56.2 (15.8–208.2) 29.5 (7.8–112.2) 3.0 (0.9–9.8) 8.9 (3.6–21.9) 8.3 (5.8–11.7)
IL-10/TNF-α2 1.9 (1.0–3.6) 1.4 (0.4–5.6) 1.0 (0.5–2.3) 1.7 (0.1–46.8) 1.0 (0.5–2.0)
1: median (range)
2: mean (95% CI)Malaria Journal 2005, 4:56 http://www.malariajournal.com/content/4/1/56
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and group 2 were combined in order to span the range of
Hb-levels. However, when the multiple regression analy-
sis was repeated for the two groups separately, the results
were similar, although the association between pLDH and
sTfR did not reach statistical significance (log RDW: group
1: P < 0.001 and group 2: P < 0.05; log sTfR group 1: P =
0.07 and group 2: P = 0.08). Persistent, microscopy nega-
tive malaria reduced the bone marrow response to the
same extent as patent malaria. Thus, the slope of the
regression line between RDW as the dependent and Hb as
the independent variable was reduced to the same extent
in microscopy negative patients with persistent malaria as
in the 405 patients with a positive microscopy compared
to patients without malaria (Figure 2, red slope, purple
slope, and green slope, respectively, P < 0.001 for the com-
parison between no malaria and both other groups).
Plasma levels of EPO showed a strong inverse correlation
with Hb (Figure 1C, R = -0.36, 95%CI: -0.40 – -0.32, P <
0.001), and neither pLDH nor HRP2 were correlated with
EPO, indicating that P. falciparum infection did not affect
the secretion of EPO (Table 2).
Forty patients in group 2 were followed up on day 7. In
these, bone marrow suppression had receded and there
was an inverse linear correlation between log RDW and
Hb (R = -0.05, 95%CI: -0.06 – -0.04, P < 0.001, Figure 3).
There was no difference between children who had a pos-
itive and those who had a negative test for pLDH on day
three (P = 0.53), but two children remained severely anae-
mic.
Cytokines
The plasma levels of TNF-α and IL-10 were comparable to
those in normal Ghanaian children without symptoms of
malaria or detectable parasitaemia [2]. There was an
inverse linear correlation between log IL10 and Hb (R = -
0.08, 95%CI: -0.14 – -0.03, P = 0.005). There was no cor-
relation between log TNF-α and Hb (P = 0.89). The regres-
sion line between RDW and Hb was not influenced by
TNFα, IL-10 or the IL-10/TNF-α ratio, irrespective of anti-
gen test results (multiple regression analysis, IL-10, P =
0.40, TNF-α, P = 0.53, IL-10/TNF-α, P = 0.40). Analyses
with sTfR as a dependent variable gave similar results (IL-
10, P = 0.78, TNF-α, P = 0.35, IL-10/TNF-α, P = 0.63). On
day 0 (i.e. prior to recruitment), patients in group 2 had
elevated plasma IL-10 (mean (95% CI) 450.4 (291.5–
609.3) pg/ml) and TNF-α (36.3 (25.7–51.3) pg/ml), but
the levels were not correlated with Hb (IL-10, P = 0.31,
TNF-α, P = 0.30, IL-10/TNF-α ratio, P = 0.21).
Discussion
Children living in areas with endemic malaria are usually
assumed to have malaria if they are hospitalized with
severe anaemia that is preceded by an acute febrile illness.
Effect of P. falciparum on erythropoietic response to anaemia Figure 1
Effect of P. falciparum on erythropoietic response to 
anaemia. Associations between haemoglobin and (A) red 
cell distribution width (RDW), (B) soluble transferrin recep-
tor (sTfR), and C. erythropoietin (EPO) in children with 
recent malaria (pLDH negative, HRP2 positive), persistent, 
submicroscopic P. falciparum infection (pLDH and HRP2 pos-
itive) or without signs of malaria (pLDH and HRP2 negative).
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Such patients often have undetectable malaria parasites
by microscopy of Giemsa-stained blood films, but their
leukocytes commonly contain detectable malaria pigment
[15]. It has previously been shown that the diagnosis may
be aided by the use of rapid antigen detection tests, which
can distinguish patients with malarial anaemia from those
with anaemia from other causes [7], and this was sup-
ported in the present study. Thus, more than 90% of the
patients with severe anaemia had detectable parasite anti-
gens compared to only one third of those with normal or
near normal Hb. Although microscopy is usually consid-
ered the gold standard for the diagnosis of malaria, these
results suggest that the antigen detection methods, in par-
ticular those based on the detection of pLDH, may be
superior to microscopy in the diagnosis of malarial anae-
mia.
In the present study, patients with detectable pLDH, a sign
of persistent parasitaemia, were distinguished from those
in whom only HRP2 could be detected as a sign of a
cleared, recent infection. Only patients with persistent
parasitaemia had signs of bone marrow suppression. This
corresponds with previous investigations in which release
of immature erythrocytes from the bone marrow coin-
cided with the time of parasite clearance [1,6] and with
findings in experimental malaria [16]. In one such study,
subpatent  P. falciparum infection in vaccinated Aotus
monkeys led to severe bone marrow suppression that was
rapidly reversed in response to mefloquine induced para-
site clearance [17].
The association between P. falciparum infection and sup-
pression of erythropoiesis has been debated. Menendez et
al. found that levels of sTfR were increased in infants with
malaria [18]. Similarly, Verhoef found increased levels of
sTfR in children with malaria and concluded that there
was no suppression of erythropoiesis [19]. However, in
these studies it was not indicated if levels of sTfR were
increased adequately compared to the degree of anaemia.
Furthermore, increased levels of sTfR found in malaria
patients might be caused by shedding of receptors from
proliferating B-lymphocytes [16]. In the present study,
however, there was no correlation between sTfR and lym-
phocyte count (data not shown). Due to the logistics of
the study it was not possible to make reticulocyte counts
but the finding that persistent, subpatent parasitaemia
was associated with reduced levels of both RDW and sTfR
strongly points toward parasite-induced suppression of
erythropoiesis. This may explain the fact that healthy
school children with so-called asymptomatic P. falciparum
infection have reduced Hb and signs of bone marrow sup-
pression [2]. Asymptomatic P. falciparum infections are
usually accepted as a necessary evil in order to maintain
immunity in individuals, who are at great and constant
risk of malarial infections [20], and this approach is prob-
ably the only realistic option in the near future. However,
data from the present study imply that the ultimate goal
of malaria control ought to be complete parasite eradica-
tion due to the detrimental effects of persistent parasitae-
mia. This is consistent with a previous clinical trial that
linked incomplete haematological recovery with lack of
parasitological cure [21]. The Hb levels in infants living
with high risk of malaria can be improved by impregnated
bednets [22], malaria chemoprophylaxis [23] and pre-
sumptive intermittent treatment [24]. It is likely that this
effect is mediated partly by a reduction in the risk of bone
marrow suppression. From a clinical point of view this
study suggests that in malarial endemic areas, antimalarial
treatment should not be withheld from severely anaemic
patients presenting with signs compatible with ongoing or
recent malaria who have not been treated for malaria,
even when parasites are undetectable by microscopy.
Controlled clinical trials should be performed to deter-
mine whether patients who have already received a full
course of antimalarial treatment would benefit from a
repeat course, and in particular, if it is important to restrict
this treatment to children with a positive pLDH test. Pae-
diatric patients that return with repeated episodes of anae-
mia are common (ref. 7) and the management of these
patients puts strain on the health system. Thus, the cost of
Table 2: Association between markers of erythropoiesis and Plasmodium antigens in multiple regression analyses with haemoglobin 
and test results for parasite derived lactate dehydrogenase (pLDH) and histidine rich protein 2 (HRP2) as explanatory variables.
pLDH HRP2 Haemoglobin
β (95% CI) P-value β (95% CI) P-value β (95% CI) P-value
Log RDW1 (%) -0.08 (-0.11–(-0.04)) <0.001 -0.04 (-0.12–0.04) 0.56 0.03 (0.02–0.04) <0.001
Log sTfR2 (nmol/l) -0.18 (-0.32–(-0.03)) 0.02 0.08 (-0.09–0.24) 0.36 0.04 (0.02–0.06) <0.001
Log EPO3 (mIU/ml) 0.13 (-0.16–0.43) 0.39 0.14 (-0.18–0.47) 0.38 0.34 (0.30–0.39) <0.001
1: Red cell distribution width
2: Soluble transferrin receptor
3: ErythropoietinMalaria Journal 2005, 4:56 http://www.malariajournal.com/content/4/1/56
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improved diagnosis and management of these cases have
the potential to benefit both the patients and the health
system.
Several studies have shown that the suppressed bone mar-
row response to anaemia, which is a general feature of
malaria, is not caused by insufficient secretion of EPO
[1,25,26], but this is disputed by other investigations [27-
29]. In agreement with the former view, similar levels of
EPO in response to low Hb were found in patients with
and without malaria. It has been suggested that the bone
marrow suppression is a direct effect of TNF-α, which is
elevated in malaria [30]. On the other hand, other inves-
tigations did not find that inflammatory cytokines to
played a role in malarial dyserythropoiesis [31]. In addi-
tion, severe malarial anaemia is associated with relatively
low TNF-α levels [32] and signs of systemic inflammation
[33,34] (Awandare et al. unpublished data) compared
with cerebral malaria and uncomplicated malaria. It is
thus possible that the effect of cytokine perturbations in
malarial anaemia is a lack of parasite control that leads to
persistence of the infection and thus indirectly causes
bone marrow suppression [32]. It has recently been pro-
posed that phagocytosed haemozoin may play a role in
the dyserythropoiesis of malaria through induction of 4-
hydroxynonenal [35].
Conclusion
This study has shown that the majority of severe anaemia
cases in children living in areas with malaria transmission
is due to malaria. This is also the case when no malaria
parasites can be detected by microscopy, in which case
antigen detection may lead to the diagnosis. These
patients have suppressed erythropoiesis, which persists
until the parasites have been cleared completely.
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Erythropoietic response to anaemia after clearance of P. falci- parum Figure 3
Erythropoietic response to anaemia after clearance 
of P. falciparum. Association between haemoglobin and red 
cell distribution width (RDW) on day 7. Regression line and 
95% confidence interval.
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Comparison of the effect of patent versus subpatent P. falci- parum infection on erythropoietic response to anaemia Figure 2
Comparison of the effect of patent versus subpatent 
P. falciparum infection on erythropoietic response to 
anaemia. Association between haemoglobin and red cell 
distribution width (RDW) in microscopy negative children 
with persistent malaria, children with microscopically detect-
able parasites and children without malaria. Regression lines 
and 95% confidence intervals.
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